AACR 2025 – BioNTech sees its first combo glimmers
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
Unharmonious ivonescimab reveal for Summit
The same trial that sent Summit up 272% sees the stock crash 36%.
Xencor could face second challenge from former partner
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Compass claims a pivotal win with tovecimig
A biliary tract cancer trial hits on response rate, but survival data will be key.
ELCC 2025 – BioNTech impresses in small-cell lung
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
